The import of pharmaceutical products to China has witnessed considerable growth from 2013 to 2023, with the value standing at $34.798 billion in 2023. The year-over-year growth rate over the past two years also reflects variability with a decrease of 4.83% in 2022 followed by a recovery of 4.38% in 2023. The compounded annual growth rate (CAGR) over the last five years averaged at 4.58%, indicating a slowing, yet consistent upward trend in import value.
Looking ahead to forecasted data from 2024 to 2028, the CAGR is expected to be 2.81%, suggesting a steady but moderate growth rate. The total growth rate over these five years is projected at 14.84%, indicating a stable increase in demand for imported pharmaceutical products.
Future trends to watch for:
- Impact of regulatory changes in China's pharmaceutical industry
- Developments in domestic pharmaceutical production capabilities
- Technological advancements and innovations within the pharmaceutical sector
- Global economic factors influencing trade and import dynamics
